Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $10.6 million.

  • Voyager Therapeutics' Current Deferred Revenue fell 5325.47% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year decrease of 5325.47%. This contributed to the annual value of $24.4 million for FY2024, which is 4311.23% down from last year.
  • As of Q3 2025, Voyager Therapeutics' Current Deferred Revenue stood at $10.6 million, which was down 5325.47% from $20.5 million recorded in Q2 2025.
  • Voyager Therapeutics' Current Deferred Revenue's 5-year high stood at $87.0 million during Q2 2022, with a 5-year trough of $5.7 million in Q1 2023.
  • For the 5-year period, Voyager Therapeutics' Current Deferred Revenue averaged around $38.9 million, with its median value being $39.2 million (2021).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 9347.08% in 2023, then soared by 80561.62% in 2024.
  • Over the past 5 years, Voyager Therapeutics' Current Deferred Revenue (Quarter) stood at $33.9 million in 2021, then soared by 75.23% to $59.4 million in 2022, then decreased by 27.78% to $42.9 million in 2023, then crashed by 43.11% to $24.4 million in 2024, then plummeted by 56.64% to $10.6 million in 2025.
  • Its Current Deferred Revenue was $10.6 million in Q3 2025, compared to $20.5 million in Q2 2025 and $21.1 million in Q1 2025.